Two Percent with Michael Easter Two Percent with Michael Easter

Should You Take Peptides? A Doctor's Evidence-Based Answer | Dr. Jordan Feigenbaum

Aug 27, 2026 · 55m

Summary

Michael Easter and Dr. Jordan Feigenbaum examine the peptide boom, distinguishing between established drugs like GLP-1s and unproven compounds like BPC-157. They highlight the lack of human clinical trials, noting that most evidence relies on animal studies or anecdotal reports. The discussion warns against unsafe sourcing from research chemical sites, which often lack quality control, and emphasizes the need for rigorous data before adopting these treatments.

Topics discussed

Intro: Therapy Gecko, Natural Causes, and Faultline Haditha promos Origin story: How Foster Kamer suggested peptides for the podcast The peptide boom: From long COVID to a cure-all for everything Sourcing concerns: Bodegas, gray markets, and sketchy suppliers Interlude: Ads for Waking Up With Ryan and Black Mother Wound Defining peptides: Chemistry, amino acids, and the FDA Bright Line Rule Types of peptides: GLP-1s, research chemicals, and compounding pharmacies Popular peptides: BPC-157, TB-500, and the 'Wolverine stack' The evidence gap: Lack of human randomized control trials Placebo effect: Sham knee surgery studies and pain perception Expert skepticism: Why big pharma hasn't pursued older peptides Safety risks: Melanotan 2, melanoma, and unknown side effects Interlude: Ads for Therapy Thursday, Natural Causes, and others Debating the hype: Patent issues and the 'lottery ticket' analogy Historical parallels: The Fen-Phen disaster and FDA trust issues Quality control: Research chemicals vs. compounding pharmacies FDA regulations: Category 2 list and industry influence on votes Why now? Normalization of injections and the biohacking movement Cost and access: Insurance barriers driving people to gray markets Interlude: Ads for Therapy Thursday, Waking Up With Ryan, and others Harm reduction: Monitoring patients who insist on using peptides Future outlook: Will peptides become mainstream or remain a fad? Outro: Final thoughts, credits, and podcast promotions
Listen ad-free on Castria